VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (6245)	1/13/1999 2:11:00 AM
From: Vector1	Read Replies (1) of 9719

HQ BGEN Report 2 Vincent next moved to the pipeline. Their stated goal is to have two or more drugs approved by 2001. The lead candidates are: Antova- (anti CD40 ligand) this is clearly the one they are most excited about. It has been through two phase IIs in ITP and Lupus and has been well tollerated. They are going to run as many as 6 different phase IIs for this compound in 99. HUGE POTENTIAL. AMEVIVE--fusion protien for moderate to severe psoriasis.Phase II date reported Q2 with Phase II commenced in 99. CVT 124--congestive heart failure. Phase II Q299 Pipeline is maturing nicely and they have a grade a ballance sheet to expand through acquisition and in licencing. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next